Lee JiEun, Jin Chul, Cho Seung-Yeon, Park Seong-Uk, Jung Woo-Sang, Moon Sang-Kwan, Park Jung-Mi, Ko Chang-Nam, Cho Ki-Ho, Kwon Seungwon
Department of Korean Medicine Cardiology and Neurology, Graduate School.
Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
Medicine (Baltimore). 2020 Aug 14;99(33):e21745. doi: 10.1097/MD.0000000000021745.
Alzheimer disease (AD) is a leading progressive neurodegenerative disease worldwide, but treating it is challenging in clinical practice. This review is aimed at evaluating the efficacy and safety of herbal medicine for treating AD.
We will search for randomized controlled trials related to the effect and safety of herbal medicine for AD in the following databases: PubMed, Cochrane Central Register of Controlled Trials, Excerpta Medica Database, China National Knowledge Infrastructure database, Oriental Medicine Advanced Searching Integrated system, Korean Traditional Knowledge Portal, and Citation Information by National Institute for Informatics. The risk of bias will be evaluated using the Cochrane risk-of-bias assessment tool. After screening the studies, a meta-analysis will be performed. The primary outcome will be the Mini-Mental State Examination score. Secondary outcomes will consist of other scales for cognitive function and other aspects, such as behavioral and psychological symptoms and plasma levels of amyloid-β.
This study will provide the current status of evidence for herbal medicine to treat AD.
The results of this review will determine the efficacy and safety of herbal medicine for AD.
Ethical approval is not required, as this study is based on a review of published research. This review will be published in a peer-reviewed journal and disseminated both electronically and in print.
Research Registry reviewregistry933.
阿尔茨海默病（AD）是全球主要的进行性神经退行性疾病，但在临床实践中治疗具有挑战性。本综述旨在评估草药治疗AD的疗效和安全性。
我们将在以下数据库中检索与草药治疗AD的效果和安全性相关的随机对照试验：PubMed、Cochrane对照试验中心注册库、医学文摘数据库、中国知网数据库、东方医学高级检索集成系统、韩国传统知识门户以及日本国立信息学研究所的文献信息。将使用Cochrane偏倚风险评估工具评估偏倚风险。筛选研究后，将进行荟萃分析。主要结局将是简易精神状态检查表评分。次要结局将包括认知功能和其他方面的其他量表，如行为和心理症状以及淀粉样β蛋白的血浆水平。
本研究将提供草药治疗AD的现有证据状况。
本综述的结果将确定草药治疗AD的疗效和安全性。
由于本研究基于对已发表研究的综述，无需伦理批准。本综述将发表在同行评审期刊上，并以电子和印刷形式传播。
Research Registry reviewregistry933。
